A Common Autoimmunity Predisposing Signal Peptide Variant of the Cytotoxic T-lymphocyte Antigen 4 Results in Inefficient Glycosylation of the Susceptibility Allele*

A common T17A polymorphism in the signal peptide of the cytotoxic T-lymphocyte antigen 4 (CTLA-4), a T-cell receptor that negatively regulates immune responses, is associated with risk for autoimmune disease. Because the polymorphism is absent from the mature protein, we hypothesized that its biological effect must involve early stages of protein processing, prior to signal peptide cleavage. Constructs representing the two alleles were compared byin vitro translation, in the presence of endoplasmic reticulum membranes. We studied glycosylation by endoglycosidase H digestion and glycosylation mutant constructs, cleavage of peptide with inhibitors, and membrane integration by ultracentrifugation and proteinase K sensitivity. A major cleaved and glycosylated product was seen for both alleles of the protein but a band representing incomplete glycosylation was markedly more abundant in the predisposing Ala allele (32.7 ± 1.0 versus 10.6% ± 1.2 for Thr,p < 10−9). In addition, differential intracellular/surface partitioning was studied with co-transfection of the alleles fused to distinct fluorescent proteins in COS-1 cells. By quantitative confocal microscopy we found a higher ratio of cell surface/total CTLAThr17 versusCTLAAla17 (p = 0.01). Our findings corroborate observations, in other proteins, that the signal peptide can determine the efficiency of post-translational modifications other than cleavage and suggest inefficient processing of the autoimmunity predisposing Ala allele as the explanation for the genetic effect.

[1]  R. Giscombe,et al.  Coding sequence 1 and promoter single nucleotide polymorphisms in the CTLA-4 gene in Wegener's granulomatosis. , 2002, The Journal of rheumatology.

[2]  Nitin J. Karandikar,et al.  The role of CTLA‐4 in induction and maintenance of peripheral T cell tolerance , 2002, European journal of immunology.

[3]  P. Rieckmann,et al.  A polymorphism in the human cytotoxic T-lymphocyte antigen 4 (CTLA4) gene (exon 1 +49) alters T-cell activation , 2002, Immunogenetics.

[4]  T. Yanagawa,et al.  Relation of three polymorphisms of the CTLA-4 gene in patients with Graves’ disease , 2002, Journal of endocrinological investigation.

[5]  S. Pearce,et al.  An association between the CTLA4 exon 1 polymorphism and early rheumatoid arthritis with autoimmune endocrinopathies. , 2002, Rheumatology.

[6]  D. Curtis,et al.  CTLA-4/CD28 gene region is associated with genetic susceptibility to coeliac disease in UK families , 2002, Journal of medical genetics.

[7]  J. Franklyn,et al.  Polymorphism of the CTLA-4 gene is associated with autoimmune hypothyroidism in the United Kingdom. , 2002, Thyroid : official journal of the American Thyroid Association.

[8]  J. Partanen,et al.  Technical Note: Linkage Disequilibrium and Disease-Associated CTLA4 Gene Polymorphisms , 2001, The Journal of Immunology.

[9]  X. Chen,et al.  Signal Peptidase and Oligosaccharyltransferase Interact in a Sequential and Dependent Manner within the Endoplasmic Reticulum* , 2001, The Journal of Biological Chemistry.

[10]  M. Fisfalen,et al.  CTLA-4 Gene Polymorphism at Position 49 in Exon 1 Reduces the Inhibitory Function of CTLA-4 and Contributes to the Pathogenesis of Graves’ Disease1 , 2000, The Journal of Immunology.

[11]  J. Dubuisson,et al.  Glycosylation of the Hepatitis C Virus Envelope Protein E1 Is Dependent on the Presence of a Downstream Sequence on the Viral Polyprotein* , 2000, The Journal of Biological Chemistry.

[12]  J. Bluestone,et al.  CTLA-4 downregulates epitope spreading and mediates remission in relapsing experimental autoimmune encephalomyelitis , 2000, Journal of Neuroimmunology.

[13]  J. Rotter,et al.  Genetic and physical mapping of a type 1 diabetes susceptibility gene (IDDM12) to a 100-kb phagemid artificial chromosome clone containing D2S72-CTLA4-D2S105 on chromosome 2q33. , 2000, Diabetes.

[14]  A Helenius,et al.  Setting the standards: quality control in the secretory pathway. , 1999, Science.

[15]  T. Mak,et al.  Cutting edge: lymphoproliferative disease in the absence of CTLA-4 is not T cell autonomous. , 1999, Journal of immunology.

[16]  P. Bousso,et al.  Defective CTLA-4 cycling pathway in Chediak-Higashi syndrome: a possible mechanism for deregulation of T lymphocyte activation. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[17]  M. Spiess,et al.  Mechanism of Endoplasmic Reticulum Retention of Mutant Vasopressin Precursor Caused by a Signal Peptide Truncation Associated with Diabetes Insipidus* , 1999, The Journal of Biological Chemistry.

[18]  M. McCarthy,et al.  The cytotoxic T lymphocyte antigen-4 is a major Graves' disease locus. , 1999, Human molecular genetics.

[19]  J. Bluestone,et al.  Molecular basis of T cell inactivation by CTLA-4. , 1998, Science.

[20]  Watson,et al.  A cytotoxic T lymphocyte antigen‐4 (CTLA‐4) gene polymorphism is associated with autoimmune Addison's disease in English patients , 1998, Clinical endocrinology.

[21]  J. Bach,et al.  CTLA-4 gene polymorphism is associated with predisposition to coeliac disease , 1998, Gut.

[22]  D. Ogrydziak,et al.  Another Factor Besides Hydrophobicity Can Affect Signal Peptide Interaction with Signal Recognition Particle* , 1998, The Journal of Biological Chemistry.

[23]  J. Bluestone,et al.  CTLA-4 regulates tolerance induction and T cell differentiation in vivo. , 1998, Journal of immunology.

[24]  C. Benoist,et al.  Cytotoxic T Lymphocyte–associated Antigen 4 (CTLA-4) Regulates the Unfolding of Autoimmune Diabetes , 1998, The Journal of experimental medicine.

[25]  N. Kuzuya,et al.  Association of CTLA-4 Gene A-G Polymorphism (IDDM12 Locus) With Acute-Onset and Insulin-Depleted IDDM as Well as Autoimmune Thyroid Disease (Graves' Disease and Hashimoto's Thyroiditis) in the Japanese Population , 1998, Diabetes.

[26]  Richard Hughey,et al.  Hidden Markov models for detecting remote protein homologies , 1998, Bioinform..

[27]  T. Sullivan,et al.  Lymphoproliferation in CTLA-4-deficient mice is mediated by costimulation-dependent activation of CD4+ T cells. , 1997, Immunity.

[28]  T. Saruta,et al.  CTLA4 gene polymorphism confers susceptibility to Graves' disease in Japanese. , 1997, Thyroid : official journal of the American Thyroid Association.

[29]  F. Schuit,et al.  CTLA‐4 gene polymorphism confers susceptibility to insulin‐dependent diabetes mellitus (IDDM) independently from age and from other genetic or immune disease markers , 1997, Clinical and experimental immunology.

[30]  J. Rotter,et al.  Insulin-dependent diabetes mellitus (IDDM) is associated with CTLA4 polymorphisms in multiple ethnic groups. , 1997, Human molecular genetics.

[31]  K. Constantine,et al.  Solution structure of human CTLA-4 and delineation of a CD80/CD86 binding site conserved in CD28 , 1997, Nature Structural Biology.

[32]  K. Kotsa,et al.  A CTLA‐4 gene polymorphism is associated with both Graves' disease and autoimmune hypothyroidism , 1997, Clinical endocrinology.

[33]  T. Strom,et al.  Induction of peripheral T cell tolerance in vivo requires CTLA-4 engagement. , 1997, Immunity.

[34]  J. Allison,et al.  Specific blockade of CTLA-4/B7 interactions results in exacerbated clinical and histologic disease in an actively-induced model of experimental allergic encephalomyelitis , 1997, Journal of Neuroimmunology.

[35]  S. Brunak,et al.  SHORT COMMUNICATION Identification of prokaryotic and eukaryotic signal peptides and prediction of their cleavage sites , 1997 .

[36]  D. Y. Thomas,et al.  Effects of inefficient cleavage of the signal sequence of HIV-1 gp 120 on its association with calnexin, folding, and intracellular transport. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[37]  J. Todd,et al.  Panning for gold: genome-wide scanning for linkage in type 1 diabetes. , 1996, Human molecular genetics.

[38]  C. June,et al.  CTLA-4 blockade enhances clinical disease and cytokine production during experimental allergic encephalomyelitis. , 1996, Journal of immunology.

[39]  Nitin J. Karandikar,et al.  CTLA-4: a negative regulator of autoimmune disease , 1996, The Journal of experimental medicine.

[40]  J. Todd,et al.  The CTLA-4 gene region of chromosome 2q33 is linked to, and associated with, type 1 diabetes. Belgian Diabetes Registry. , 1996, Human molecular genetics.

[41]  J. Winther,et al.  Competition between folding and glycosylation in the endoplasmic reticulum. , 1996, The EMBO journal.

[42]  K. Bennett,et al.  Intracellular trafficking of CTLA-4 and focal localization towards sites of TCR engagement. , 1996, Immunity.

[43]  J. Allison,et al.  CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells , 1996, The Journal of experimental medicine.

[44]  L. Kasturi,et al.  The Amino Acid at the X Position of an Asn-X-Ser Sequon Is an Important Determinant of N-Linked Core-glycosylation Efficiency (*) , 1996, The Journal of Biological Chemistry.

[45]  H. Griesser,et al.  Lymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4 , 1995, Science.

[46]  J. Bluestone,et al.  Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. , 1995, Immunity.

[47]  Peter S. Linsley,et al.  Cytotoxic T Lymphocyte-associated Molecule-4, a High Avidity Receptor for CD80 and CD86, Contains an Intracellular Localization Motif in Its Cytoplasmic Tail (*) , 1995, The Journal of Biological Chemistry.

[48]  James R. Eshleman,et al.  The Hydroxy Amino Acid in an Asn-X-Ser/Thr Sequon Can Influence N-Linked Core Glycosylation Efficiency and the Level of Expression of a Cell Surface Glycoprotein (*) , 1995, The Journal of Biological Chemistry.

[49]  Henry M. Kronenberg,et al.  Inefficient Membrane Targeting, Translocation, and Proteolytic Processing by Signal Peptidase of a Mutant Preproparathyroid Hormone Protein (*) , 1995, The Journal of Biological Chemistry.

[50]  P. Linsley,et al.  CTLA-4 can function as a negative regulator of T cell activation. , 1994, Immunity.

[51]  M. Ito,et al.  Possible involvement of inefficient cleavage of preprovasopressin by signal peptidase as a cause for familial central diabetes insipidus. , 1993, The Journal of clinical investigation.

[52]  M. Racchi,et al.  Human coagulation factor X deficiency caused by a mutant signal peptide that blocks cleavage by signal peptidase but not targeting and translocation to the endoplasmic reticulum. , 1993, The Journal of biological chemistry.

[53]  Ylva Gavel,et al.  Sequence differences between glycosylated and non-glycosylated Asn-X-Thr/Ser acceptor sites: implications for protein engineering , 1990, Protein engineering.

[54]  G. Deléage,et al.  A computerized version of the Chou and Fasman method for predicting the secondary structure of proteins. , 1987, Analytical biochemistry.

[55]  Thomas A. Kunkel,et al.  Rapid and efficient site-specific mutagenesis without phenotypic selection. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[56]  R. Doolittle,et al.  A simple method for displaying the hydropathic character of a protein. , 1982, Journal of molecular biology.